A Phase 1 Study of Nivolumab (BMS-936558) Plus Sunitinib, Pazopanib or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma

Trial Profile

A Phase 1 Study of Nivolumab (BMS-936558) Plus Sunitinib, Pazopanib or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Nivolumab (Primary) ; Ipilimumab; Pazopanib; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms CheckMate 016; CheckMate016
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 05 Jul 2017 Results from the nivolumab plus ipilimumab cohorts of the study (n=94), published in the Journal of Clinical Oncology.
    • 11 Oct 2016 Updated safety results presented at the 41st European Society for Medical Oncology Congress
    • 09 Oct 2016 According to a Bristol-Myers Squibb media release, results from the study will be presented at the 2016 European Society for Medical Oncology (ESMO) Congress during a poster session.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top